Quotient Sciences, a drug development and manufacturing accelerator, has announced a £6.3m ($8.6m) investment in its recently acquired manufacturing facility in Alnwick, UK. The investment will significantly expand the company’s drug substance manufacturing capability and will create 80 new jobs over the next three years.
The company acquired the Alnwick facility from Arcinova in February 2021 to expand its service portfolio to include drug substance, drug product and clinical testing capabilities all under one organisation. The acquisition enables the company to support customers with an end to end offering from candidate selection through commercial product launch. The investment will repurpose a 1500 sqm footprint to incorporate additional equipment and technologies, expanding the number of molecules developed each year.
Additional equipment including digital control and data capture capabilities, are hoped to ensure robust transfer from laboratory to multi-kilo scale production. Processing equipment with developments in modular continuous technology will improve responsiveness and agility for manufacturing processes. These updates will be combined with a five-fold increase in scale to expand the company’s capacity by more than 10 times, it claims.
“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Quotient Sciences SVP Candidate Development Services Roger Kilburn. “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”